0900191106SI.Pdf

Total Page:16

File Type:pdf, Size:1020Kb

0900191106SI.Pdf Supporting Information Ong et al. 10.1073/pnas.0900191106 SI Methods volume of DMSO is then added to 2 mg of heavy HeLaS3 as a 13 13 15 ␮ Materials and Reagents. L-arginine- C6 and L-lysine- C6 N2 control. 25 L of 50% of SM-bead is added to both light and were from Sigma Isotec. The cell culture media, Roswell Park heavy lysates in SC experiments. Memorial Institute-1640 (RPMI) deficient in arginine, lysine Affinity enrichments are incubated overnight (Ϸ16 h) on an and methioine, was a custom media preparation from Caisson end-over-end rotator at 4 °C. After incubation, the tubes are ϫ Laboratories. All other L-amino acids were obtained from spun at 1000 g on a benchtop centrifuge to pellet the beads. Sigma. Dialyzed serum was obtained from SAFC-Sigma. Trypsin The supernatant is aspirated, taking care to avoid disturbing the was from Promega and HeLaS3 and H1299 were a kind gift from beads. In BC experiments, beads are combined at the first wash Dr. James Bradner. A PC-12 rat pheochromocytoma cell line for subsequent washing steps. For SC experiments, each tube in stably expressing hErbB4 and GFP was generated with neomycin a set is washed with ModRIPA buffer at least once (twice with selection and 2 independent pcDNA3-neomycin (Invitrogen) high levels of soluble competition) to remove excess soluble constructs. Other cell lines were from ATCC. small molecule competitor. Beads from the 2 tubes were then be Antibodies against the following proteins were used: Anti- combined for later washing steps. In high stringency experi- FKBP1A and anti-MTAP (Abcam); anti-FKBP2 and anti- ments, a wash buffer (high stringency HS) containing ModRIPA FKBP5 R&D Systems); anti-FKBP4 (Bethyl Laboratories); anti- and 0.2% SDS was used to wash beads instead. After the third FKBP8 (US Biological); anti-FKBP10 (listed in the article as and final wash, beads are collected by spinning at 1000 ϫ g and FKBP9/10) (BD Transduction Laboratories). Secondary anti- the wash is aspirated leaving Ϸ20 ␮L of buffer in the tube. bodies were all purchased from Sigma. Anti-GST antibody was from GE Healthcare (Piscataway, NJ). All other reagents and 1D-SDS/PAGE and MS Analysis. Proteins enriched in SILAC affinity chemicals used were of the highest grade available. pull-downs were reduced and alkylated, on bead, in 2 mM DTT and 10 mM iodoacetamide respectively. One part LDS buffer SILAC Media Preparation and Cell Culture Conditions. We followed (Invitrogen) was added to 3 parts sample (including beads) and all standard SILAC media preparation and labeling steps as tubes heated to 70 °C for 10 min. Proteins were resolved on a described in ref. 1. Briefly, 15 mg/L of L-methionine was added 4–12% gradient 1.5 mm thick Bis-Tris gel with Mes running to base media according to standard formulations for standard buffer (Nupage, Invitrogen) and Coomassie stained (Simply RPMI. This base media was divided into 2 and either ‘‘light’’ Blue, Invitrogen). Gel lanes were excised into 6 pieces and then forms of arginine and lysine or ‘‘heavy’’ L-arginine-U-13C6 (87.2 further cut into 1.5 mm cubes. The gel pieces were further mg/L) and L-lysine-13C615N2 (155 mg/L) was added to generate destained in a solution containing 50% EtOH and 50% 50 mM the 2 SILAC labeling mediums. Each medium with the full ammonium bicarbonate, then dehydrated in 100% EtOH before complement of amino acids was sterile filtered through a 0.22 addition of sufficient trypsin (12.5 ng/␮L) to swell the gel pieces ␮M filter (Milipore). completely. An additional 100 ␮L of 50 mM ammonium bicar- HeLa S3 cells were grown in RPMI labeling media, prepared bonate was added before incubating at 37 °C overnight on a as described above, supplemented with 2 mM L-glutamine, and thermomixer (Eppendorf). Enzymatic digestion was stopped by 5% dialyzed FBS plus antibiotics, in a humidified atmosphere the addition of 100 ␮L of 1% TFA to tubes. A second extraction ␮ with 5% CO2 in air. Cells were grown for at least 6 cell divisions with 300 L of 0.1% TFA was combined with the first extract and in labeling media, initially growing in flasks but expanded into the peptides from each gel slice cleaned up on C18 StageTips (2). 2L spinner flasks on a magnetic stir plate to provide larger Peptides were eluted in 50 ␮L of 80% acetonitrile/0.1% TFA and cultures. dried down in a evaporative centrifuge to remove organic solvents. The peptides were then resuspended by vortexing in 7 Biochemical Purification with Small Molecule Affinity Matrices. Sep- ␮L of 0.1% TFA and analyzed by nanoflow-LCMS with an arate cultures of HeLaS3 cells SILAC labeled either with Agilent 1100 with autosampler and a LTQ-Orbitrap. Peptides L-arginine and L-lysine (light) or L-arginine-13C6 and L-lysine- were resolved on a 10 cm column, made in-house by packing a 13C6-15N2 (heavy) are lysed in ice-chilled ModRIPA buffer (low self-pulled 75 ␮m I.D. capillary, 15 ␮m tip (P-2000 laser based stringency buffer LS) containing 1% Nonidet P-40, 0.1% Na puller, Sutter Instruments) column with 3 ␮m Reprosil-C18-AQ deoxycholate, 150 mM NaCl, 1 mM EDTA, 50 mM Tris, pH 7.5, beads (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany) and protease inhibitors (Complete tablets, Roche Applied Sci- with an analytical flowrate of 200 nL/min and a 58 min linear ence, Indianapolis, IN). Lysates are vortexed intermittently while gradient (Ϸ0.57%B/min) from 0.1% formic acid in water to 0.1% chilled on ice for 10 min and clarified by spinning at 14,000 ϫ g. formic acid/90% acetonitrile. The run time was 108 min for a Protein concentrations of light and heavy lysates are estimated single sample, including sample loading and column recondi- with the Protein Assay Dye Reagent Concentrate (Bio-Rad, tioning. Hercules CA) and equalized. The protein concentrations of We used a MS method with a master Orbitrap full scan (60,000 lysates can vary between 1.7 to 2.2 mg/mL, affinity enrichments resolution) and data dependent LTQ MS/MS scans for the top are performed in lysate volumes between 1 mL to 1.4 mL in a 1.5 5 precursors (excluding z ϭ 1) from the Orbitrap scan. Each cycle mL microcentrifuge tube. was Ϸ2 secs long. MS raw files were processed for protein In bead control (BC) experiments, 2 mg of light HeLaS3 lysate identification and quantitation using extract࿝msn.exe (Thermo), is incubated with 25 ␮L of 50% slurry of EtOH-bead while 2 mg Mascot (Ver. 2.1.03 Matrixscience), and academic software, of heavy lysate is incubated with 25 ␮L of 50% small molecule DTASupercharge and MSQuant (CEBI, open-source http:// affinity beads (SM-bead). This is termed a ‘‘forward’’ label msquant.sourceforge.net). MS/MS peak lists in Mascot Generic experiment. In the ‘‘reverse’’ experiment, the lysates are Format were generated using extract࿝msn.exe and DTASuper- swapped for each bead type. In a ‘‘forward’’ soluble competitor charge and searched with Mascot using IPI human ver.3.32 experiment, the appropriate amount of small molecule (in (http://ebi.ac.uk) with a concatenated decoy database containing DMSO) is added to 2 mg of light HeLaS3 lysate. An equal randomized sequences from the same database. Common con- Ong et al. www.pnas.org/cgi/content/short/0900191106 1of15 taminants like BSA, trypsin etc. were also added to the database. FKBP10/FKBP9 Antibody Cross-Specificity Determined by Immunopre- Variable modifications used were oxidized methionine, argi- cipitation and MS (IP-MS). In Western blot analysis experiments to 13 13 15 nine- C6, lysine- C6 N2, and carbamidomethyl-cysteine was a validate our IPL ligand SILAC TargetID data, we found the fixed modification. The precursor mass tolerance used in the FKBP10 antibody (BD Transduction Laboratories, Cat. No. search was 15 ppm and fragment mass tolerance was 0.7 Da. 610648) yielded a strong band at Ϸ63 kDa in IPL ligand Proteins with a minimum Mascot score of 66 (at least 1 peptide pull-downs with AP-1480, ProAP-1480, and AP-1497. This was with score Ͼ66) and peptides with score Ͼ20 were quantified by not consistent with our SILAC data for FKBP10, but matched MSQuant. Only proteins with a minimum of 2 quantifiable the compound specificity profile for FKBP9. Because FKBP9 peptides were included in our dataset. The false positive rate for and FKBP10 are very similar in length, 570 aa and 582 aa protein identification is Ͻ1% and Ͻ5% at the peptide level, as respectively and are 58% identical at the amino acid level determined using the decoy database strategy. (BlastP), we hypothesized that the antibody used in our exper- iment was cross-reacting with both proteins. We evaluated this Statistical Analysis of SC Experiments. To model log2 protein ratio with an IP-MS experiment. We incubated 10 ␮g of antibody and values from SC experiments, we adapted the empirical Bayes 50 ␮L of a 50% slurry of Protein G beads with 2 mg of HeLaS3 framework developed by Efron (3) to compute the posterior lysate in our usual pull-down conditions. We used Protein probability that a ratio value arises from the null distribution. G-bead alone with lysate in a separate pull-down as a control. Briefly, by application of Bayes’s theorem, this quantity is Beads were washed, proteins reduced, alkylated, resolved on a Ϸ computed as Pr(Z ϭ 0͉X) ϭ [Pr(X͉Z ϭ 0)Pr(Z ϭ 0)]/Pr(X) where 1D-SDS/PAGE gel and the molecular mass bands between 60 Z is a binary variable taking the value of 1 if the protein is bound to 98 kDa were excised for MS analysis.
Recommended publications
  • Fkbp10 (NM 010221) Mouse Untagged Clone – MC201811 | Origene
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for MC201811 Fkbp10 (NM_010221) Mouse Untagged Clone Product data: Product Type: Expression Plasmids Product Name: Fkbp10 (NM_010221) Mouse Untagged Clone Tag: Tag Free Symbol: Fkbp10 Synonyms: AI325255; FKBP-10; FKBP-65; Fkbp-rs1; Fkbp1-rs; Fkbp6; FKBP65; Fkbprp Vector: PCMV6-Kan/Neo E. coli Selection: Kanamycin (25 ug/mL) Cell Selection: Neomycin This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 3 Fkbp10 (NM_010221) Mouse Untagged Clone – MC201811 Fully Sequenced ORF: >BC029546 sequence for NM_010221 GTCCGCTCTCACTGCCGGCGTCCCTGGTCTGGGCACCATGTTCCTTGTGGGGTCCTCCAGCCACACCCTC CATCGGCTCCGCATACTGCCGTTGCTGTTGCTTCTACAGACCTTGGAGAGGGGACTGGGCCGTGCCAGCC CGGCCGGAGCCCCCTTGGAAGATGTGGTCATCGAGAGATACCACATCCCTCGGGCCTGTCCCCGAGAAGT GCAGATGGGGGATTTTGTGCGTTACCACTACAATGGCACTTTCGAAGACGGGAAAAAGTTTGACTCCAGC TATGACCGTAGCACCCTGGTGGCCATCGTTGTGGGCGTAGGCCGCCTCATCACCGGCATGGACCGGGGTC TCATGGGCATGTGTGTCAACGAGCGCCGCCGCCTCATTGTGCCTCCCCACCTGGGCTACGGCAGCATCGG TGTGGCGGGCCTCATCCCCCCTGATGCCACCCTCTATTTTGACGTGGTCCTGCTGGACGTGTGGAACAAA GCAGACACGGTGCAGTCAACTATCCTCCTGCGCCCTCCCTACTGCCCCCGAATGGTGCAGAACAGTGACT TTGTGCGCTATCACTACAATGGCACTCTGCTGGATGGCACTGCCTTTGACAACAGCTACAGTAGGGGAGG CACTTATGACACCTACATCGGCTCTGGTTGGCTGATCAAAGGCATGGACCAGGGGCTGCTGGGCATGTGC
    [Show full text]
  • Identifying Novel Actionable Targets in Colon Cancer
    biomedicines Review Identifying Novel Actionable Targets in Colon Cancer Maria Grazia Cerrito and Emanuela Grassilli * Department of Medicine and Surgery, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy; [email protected] * Correspondence: [email protected] Abstract: Colorectal cancer is the fourth cause of death from cancer worldwide, mainly due to the high incidence of drug-resistance toward classic chemotherapeutic and newly targeted drugs. In the last decade or so, the development of novel high-throughput approaches, both genome-wide and chemical, allowed the identification of novel actionable targets and the development of the relative specific inhibitors to be used either to re-sensitize drug-resistant tumors (in combination with chemotherapy) or to be synthetic lethal for tumors with specific oncogenic mutations. Finally, high- throughput screening using FDA-approved libraries of “known” drugs uncovered new therapeutic applications of drugs (used alone or in combination) that have been in the clinic for decades for treating non-cancerous diseases (re-positioning or re-purposing approach). Thus, several novel actionable targets have been identified and some of them are already being tested in clinical trials, indicating that high-throughput approaches, especially those involving drug re-positioning, may lead in a near future to significant improvement of the therapy for colon cancer patients, especially in the context of a personalized approach, i.e., in defined subgroups of patients whose tumors carry certain mutations. Keywords: colon cancer; drug resistance; target therapy; high-throughput screen; si/sh-RNA screen; CRISPR/Cas9 knockout screen; drug re-purposing; drug re-positioning Citation: Cerrito, M.G.; Grassilli, E.
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • Mouse FKBP10 ORF Mammalian Expression Plasmid, N-His Tag
    Mouse FKBP10 ORF mammalian expression plasmid, N-His tag Catalog Number: MG5A1953-NH General Information Plasmid Resuspension protocol Gene : FK506 binding protein 10 1. Centrifuge at 5,000×g for 5 min. Official Symbol : FKBP10 2. Carefully open the tube and add 100 l of sterile water to Synonym : Fkbp6; FKBP65; Fkbprp; FKBP-10; dissolve the DNA. FKBP-65; AI325255; Fkbp-rs1; Fkbp1-rs 3. Close the tube and incubate for 10 minutes at room Source : Mouse temperature. cDNA Size: 1746bp 4. Briefly vortex the tube and then do a quick spin to RefSeq : NM_010221.2 concentrate the liquid at the bottom. Speed is less than Description 5000×g. Lot : Please refer to the label on the tube 5. Store the plasmid at -20 ℃. Vector : pCMV3-SP-N-His Shipping carrier : Each tube contains approximately 10 μg of lyophilized plasmid. The plasmid is ready for: Storage : • Restriction enzyme digestion The lyophilized plasmid can be stored at ambient temperature • PCR amplification for three months. • E. coli transformation Quality control : • DNA sequencing The plasmid is confirmed by full-length sequencing with primers in the sequencing primer list. E.coli strains for transformation (recommended Sequencing primer list : but not limited) pCMV3-F: 5’ CAGGTGTCCACTCCCAGGTCCAAG 3’ Most commercially available competent cells are appropriate for pcDNA3-R : 5’ GGCAACTAGAAGGCACAGTCGAGG 3’ the plasmid, e.g. TOP10, DH5α and TOP10F´. Or Forward T7 : 5’ TAATACGACTCACTATAGGG 3’ ReverseBGH : 5’ TAGAAGGCACAGTCGAGG 3’ pCMV3-F and pcDNA3-R are designed by Sino Biological Inc. Customers can order the primer pair from any oligonucleotide supplier. Manufactured By Sino Biological Inc., FOR RESEARCH USE ONLY.
    [Show full text]
  • Supplementary Table 3
    Supplemental Table 1 M e13 ∆∆Ct e13 M e15 ∆∆Ct e15 chromogranin A -3,26 (9,6 ↓ ) -6,29 (78 ↓ ) -2,56 (5,9 ↓ ) -6,57 (95 ↓ ) crystallin, beta A2 -0,95 (1,9 ↓ ) -4,57 (24 ↓ ) -1,82 (3,5 ↓ ) -4 (16 ↓ ) cyclin-dependent kinase inhibitor 1A (P21) -1,15 (2,2 ↓ ) -1,41 (2,7 ↓ ) -0,36 (1,3 ↓ ) 0,29 (1,2 ↑ ) cytochrome P450, family 4, subfamily b, polypeptide 1 -0,68 (1,6 ↓ ) 0,16 (1,1 ↑ ) -0,56 (1,5 ↓ ) -0,08 (1,1 ↓ ) myelin transcription factor 1 -1,28 (2,4 ↓ ) -2,62 (6,1 ↓ ) -1,46 (2,8 ↓ ) -3,59 (12 ↓ ) neurogenic differentiation 2 -0,06 (1,0 → ) NA -1,34 (2,5 ↓ ) NA neuronatin 0,14 (1,1 ↑ ) 0,12 (1,1 ↑ ) -0,79 (1,7 ↓ ) -2,02 (4,1 ↓ ) protocadherin 21 -1,62 (3,1 ↓ ) -5,71 (52 ↓ ) -1,77 (3,4 ↓ ) -6,41 (85 ↓ ) regulated endocrine-specific protein 18 -2,1 (4,3 ↓ ) -4,73 (27 ↓ ) -1,55 (2,9 ↓ ) -5,09 (34 ↓ ) retinol binding protein 4, plasma -1,68 (3,2 ↓ ) -1,52 (2,9 ↓ ) -1,53 (2,9 ↓ ) -2,15 (4,4 ↓ ) rhomboid, veinlet-like 4 (Drosophila) -1,14 (2,2 ↓ ) -0,29 (1,2 ↓ ) -1,09 (2,1 ↓ ) -0,58 (1,5 ↓ ) sestrin 2 -0,78 (1,7 ↓ ) -0,84 (1,8 ↓ ) -0,67 (1,6 ↓ ) -0,61 (1,5 ↓ ) synaptotagmin 13 -1,63 (3,1 ↓ ) -2,59 (6,0 ↓ ) -1,77 (3,4 ↓ ) -2,71 (6,5 ↓ ) t-complex protein 11 -0,48 (1,4 ↓ ) -1,35 (2,5 ↓ ) -0,68 (1,6 ↓ ) -2,83 (7,1 ↓ ) -0,62 (1,5 ↓ ) -0,76 (1,7 ↓ ) transmembrane 4 superfamily member 2 -0,29 (1,2 ↓ ) -0,55 (1,5 ↓ ) -0,67 (1,6 ↓ ) -0,38 (1,3 ↓ ) 2510004L01Rik -0,7 (1,6 ↓ ) -1,58 (3,0 ↓ ) -0,07 (1,0 → ) 0,16 (1,1 ↑ ) C81234 -3,12 (8,7 ↓ ) -7,75 (215 ↓ ) -2,29 (4,9 ↓ ) -4,86 (29 ↓ ) Insulin 2 NM -9,89 (948 ↓ ) NM -14,2 (18820 ↓ ) Neurogenin 3 NM NA
    [Show full text]
  • A Key Actor of Collagen Crosslinking in Clear Cell Renal Cell Carcinoma
    www.aging-us.com AGING 2021, Vol. 13, No. 15 Research Paper FK506 binding protein 10: a key actor of collagen crosslinking in clear cell renal cell carcinoma Yubai Zhang1,4, Yue Yin2, Sijia Liu3, Lei Yang1,4, Changhua Sun4, Ruihua An1 1Department of Urology Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China 2Department of Oncology Radiotherapy, The Second Affiliated Hospital of Harbin Medical University, Harbin, China 3Department of Gynecological Radiotherapy, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China 4Department of Urology Surgery, The First Hospital of Harbin, Harbin, China Correspondence to: Ruihua An; email: [email protected], https://orcid.org/0000-0002-7041-2014 Keywords: FKBP10, clear cell renal cell carcinoma, collagen synthesis, prognosis Received: May 27, 2021 Accepted: July 10, 2021 Published: August 13, 2021 Copyright: © 2021 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Clear cell renal cell carcinoma (ccRCC) is the most common type of malignant tumor in the kidney. With numbers of patients whose physical condition or tumor stage not suitable for radical surgery, they only have a narrow choice of using VEGF/mTOR targeted drugs to control their tumors, but ccRCC often shows resistance to these drugs. Therefore, identifying a new therapeutic target is of urgent necessity. In this study, for the first time, we concluded from bioinformatics analyses and in vitro research that FK506 binding protein 10 (FKBP10), together with its molecular partner Lysyl hydroxylase 2 (LH2/PLOD2), participate in the process of type I collagen synthesis in ccRCC via regulating crosslinking of pro-collagen chains.
    [Show full text]
  • GAK and PRKCD Are Positive Regulators of PRKN-Independent
    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.05.369496; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 GAK and PRKCD are positive regulators of PRKN-independent 2 mitophagy 3 Michael J. Munson1,2*, Benan J. Mathai1,2, Laura Trachsel1,2, Matthew Yoke Wui Ng1,2, Laura 4 Rodriguez de la Ballina1,2, Sebastian W. Schultz2,3, Yahyah Aman4, Alf H. Lystad1,2, Sakshi 5 Singh1,2, Sachin Singh 2,3, Jørgen Wesche2,3, Evandro F. Fang4, Anne Simonsen1,2* 6 1Division of Biochemistry, Department of Molecular Medicine, Institute of Basic Medical Sciences, University of Oslo 7 2Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, N-0316, Oslo, Norway. 8 3Department of Molecular Cell Biology, The Norwegian Radium Hospital Montebello, N-0379, Oslo, Norway 9 4Department of Clinical Molecular Biology, University of Oslo and Akershus University Hospital, 1478 Lørenskog, Norway 10 11 Keywords: GAK, Cyclin G Associated Kinase, PRKCD, Protein Kinase C Delta, Mitophagy, DFP, 12 DMOG, PRKN 13 14 *Corresponding Authors: 15 [email protected] 16 [email protected] 17 bioRxiv preprint doi: https://doi.org/10.1101/2020.11.05.369496; this version posted November 5, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • FKBP10 and Bruck Syndrome
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector LETTERS TO THE EDITOR FKBP10 and Bruck Syndrome: none of them overlapped with either of the two previously described Bruck syndrome loci, confirming that these Phenotypic Heterogeneity patients have Bruck syndrome 3 (BKS3).6,7 One area of or Call for Reclassification? overlap between the two patients was identified on 17q21.2, spanning 1.5Mb of genomic DNA that contains 91 genes. FKBP10, which encodes FKBP65, an extracellular matrix binding protein,8 was an attractive candidate in To the Editor: We read with interest the recent paper by that interval. Sequencing of the entire coding and the Alanay et al., who describe the first human patients with flanking intronic sequence revealed the presence of a FKBP10 (MIM 607063) mutations and conclude that homozygous 8 bp insertion (c.1023insGGAGAATT) along this adds to the growing list of autosomal-recessive non- with resulting frameshift and premature truncation of syndromic osteogenesis imperfecta (OI) genes (MIM the protein (p.T342GfsX367). 610968).1 This is in contrast to our experience with an Interestingly, the OI phenotype that Alanay et al. extremely rare form of OI called Bruck syndrome (MIM described in association with the two mutations is much 259450 and 609220), in which multiple joint contracture more severe than the one we describe here.1 It may be is a prominent finding.2 Below we show this syndrome hard to attribute this to the allelic difference because one to be caused by a mutation in the same gene.
    [Show full text]
  • Produktinformation
    Produktinformation Diagnostik & molekulare Diagnostik Laborgeräte & Service Zellkultur & Verbrauchsmaterial Forschungsprodukte & Biochemikalien Weitere Information auf den folgenden Seiten! See the following pages for more information! Lieferung & Zahlungsart Lieferung: frei Haus Bestellung auf Rechnung SZABO-SCANDIC Lieferung: € 10,- HandelsgmbH & Co KG Erstbestellung Vorauskassa Quellenstraße 110, A-1100 Wien T. +43(0)1 489 3961-0 Zuschläge F. +43(0)1 489 3961-7 [email protected] • Mindermengenzuschlag www.szabo-scandic.com • Trockeneiszuschlag • Gefahrgutzuschlag linkedin.com/company/szaboscandic • Expressversand facebook.com/szaboscandic FKBP10 Recombinant Protein (OPCD03243) Data Sheet Product Number OPCD03243 Product Page http://www.avivasysbio.com/fkbp10-recombinant-protein-opcd03243.html Product Name FKBP10 Recombinant Protein (OPCD03243) Size 10 ug Gene Symbol FKBP10 Alias Symbols 65kDa, 65 kDa FK506-binding protein, 65 kDa FKBP, AI325255, FK506-binding protein 10, FKBP-10, Fkbp1-rs, Fkbp6, Fkbp65, FKBP65, FKBP-65 , Fkbprp, Fkbp-rs, Fkbp-rs1, Immunophilin FKBP65, Peptidyl-prolyl cis-trans isomerase FKBP10, PPIase FKBP10, Rotamase Molecular Weight 30 kDa Product Format Lyophilized Tag N-terminal His Tag Conjugation Unconjugated NCBI Gene Id 14230 Host E.coli Purity > 95% Source Prokaryotic Expressed Recombinant Official Gene Full Name FK506 binding protein 10 Description of Target PPIases accelerate the folding of proteins during protein synthesis. Reconstitution and Storage Reconstitute in PBS or others. Store at 2-8C for one month. Aliquot and store at -80C for 12 months. Avoid repeated freeze/thaw cycles. Additional Information Endotoxin Level: < 1.0 EU per 1 ug (determined by the LAL method) Additional Information Residues: Val316 - Asp573 Lead Time Domestic: within 1-2 weeks delivery International: 1-3 weeks Formulation Lyophilized in PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
    [Show full text]
  • Activation of Diverse Signalling Pathways by Oncogenic PIK3CA Mutations
    ARTICLE Received 14 Feb 2014 | Accepted 12 Aug 2014 | Published 23 Sep 2014 DOI: 10.1038/ncomms5961 Activation of diverse signalling pathways by oncogenic PIK3CA mutations Xinyan Wu1, Santosh Renuse2,3, Nandini A. Sahasrabuddhe2,4, Muhammad Saddiq Zahari1, Raghothama Chaerkady1, Min-Sik Kim1, Raja S. Nirujogi2, Morassa Mohseni1, Praveen Kumar2,4, Rajesh Raju2, Jun Zhong1, Jian Yang5, Johnathan Neiswinger6, Jun-Seop Jeong6, Robert Newman6, Maureen A. Powers7, Babu Lal Somani2, Edward Gabrielson8, Saraswati Sukumar9, Vered Stearns9, Jiang Qian10, Heng Zhu6, Bert Vogelstein5, Ben Ho Park9 & Akhilesh Pandey1,8,9 The PIK3CA gene is frequently mutated in human cancers. Here we carry out a SILAC-based quantitative phosphoproteomic analysis using isogenic knockin cell lines containing ‘driver’ oncogenic mutations of PIK3CA to dissect the signalling mechanisms responsible for oncogenic phenotypes induced by mutant PIK3CA. From 8,075 unique phosphopeptides identified, we observe that aberrant activation of PI3K pathway leads to increased phosphorylation of a surprisingly wide variety of kinases and downstream signalling networks. Here, by integrating phosphoproteomic data with human protein microarray-based AKT1 kinase assays, we discover and validate six novel AKT1 substrates, including cortactin. Through mutagenesis studies, we demonstrate that phosphorylation of cortactin by AKT1 is important for mutant PI3K-enhanced cell migration and invasion. Our study describes a quantitative and global approach for identifying mutation-specific signalling events and for discovering novel signalling molecules as readouts of pathway activation or potential therapeutic targets. 1 McKusick-Nathans Institute of Genetic Medicine and Department of Biological Chemistry, Johns Hopkins University School of Medicine, 733 North Broadway, BRB 527, Baltimore, Maryland 21205, USA.
    [Show full text]
  • HSP90-Incorporating Chaperome Networks As Biosensor for Disease-Related Pathways in Patient- Specific Midbrain Dopamine Neurons
    ARTICLE DOI: 10.1038/s41467-018-06486-6 OPEN HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient- specific midbrain dopamine neurons Sarah Kishinevsky1,2,3,4, Tai Wang3, Anna Rodina3, Sun Young Chung1,2, Chao Xu3, John Philip5, Tony Taldone3, Suhasini Joshi3, Mary L. Alpaugh3,14, Alexander Bolaender3, Simon Gutbier6, Davinder Sandhu7, Faranak Fattahi1,2, Bastian Zimmer1,2, Smit K. Shah3, Elizabeth Chang5, Carmen Inda3,15, John Koren 3rd3,16, Nathalie G. Saurat1,2, Marcel Leist 6, Steven S. Gross7, Venkatraman E. Seshan8, Christine Klein9, Mark J. Tomishima1,2,10, Hediye Erdjument-Bromage11,12, Thomas A. Neubert 11,12, Ronald C. Henrickson5, 1234567890():,; Gabriela Chiosis3,13 & Lorenz Studer1,2 Environmental and genetic risk factors contribute to Parkinson’s Disease (PD) pathogenesis and the associated midbrain dopamine (mDA) neuron loss. Here, we identify early PD pathogenic events by developing methodology that utilizes recent innovations in human pluripotent stem cells (hPSC) and chemical sensors of HSP90-incorporating chaperome networks. We show that events triggered by PD-related genetic or toxic stimuli alter the neuronal proteome, thereby altering the stress-specific chaperome networks, which produce changes detected by chemical sensors. Through this method we identify STAT3 and NF-κB signaling activation as examples of genetic stress, and phospho-tyrosine hydroxylase (TH) activation as an example of toxic stress-induced pathways in PD neurons. Importantly, pharmacological inhibition of the stress chaperome network reversed abnormal phospho- STAT3 signaling and phospho-TH-related dopamine levels and rescued PD neuron viability. The use of chemical sensors of chaperome networks on hPSC-derived lineages may present a general strategy to identify molecular events associated with neurodegenerative diseases.
    [Show full text]